View Future GrowthPharmaCorp Rx 과거 순이익 실적과거 기준 점검 0/6PharmaCorp Rx 의 수입은 연평균 -29.9%의 비율로 감소해 온 반면, Consumer Retailing 산업은 연평균 0.9%의 비율로 감소했습니다. 매출은 연평균 117.5%의 비율로 증가해 왔습니다.핵심 정보-29.86%순이익 성장률39.13%주당순이익(EPS) 성장률Consumer Retailing 산업 성장률10.26%매출 성장률117.55%자기자본이익률-2.93%순이익률-6.71%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).Reported Earnings • Aug 18Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024)Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024).모든 업데이트 보기Recent updatesRecent Insider Transactions • Jul 17Executive Chairperson recently bought CA$88k worth of stockOn the 14th of July, Alan Simpson bought around 173k shares on-market at roughly CA$0.51 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Alan has been a buyer over the last 12 months, purchasing a net total of CA$1.1m worth in shares.공고 • Jul 14PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 10.00008 million.PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 10.00008 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 19,608,000 Price\Range: CAD 0.51 Discount Per Security: CAD 0.0306공고 • Jul 07PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) entered into definitive share purchase agreement to acquire Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on April 28, 2026. A cash consideration of CAD 24.2 million will be paid by PharmaCorp Rx Inc. subject to customary adjustments. As part of consideration, CAD 24.2 million is paid towards interests of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada. The consideration is expected to be funded using the Corporation’s existing cash resources. In addition, the Corporation has also entered into non-binding letters of intent (“LOIs”) in respect of four additional pharmacy acquisitions. All locations will continue to be operated by their existing managing pharmacists, ensuring continuity of care, preserving patient relationships, and supporting a seamless transition and integration into the PharmaCorp platform. The transaction is subject to customary closing conditions. The Transaction is expected to close within 60 days. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on July 6, 2026.Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).공고 • Nov 29PharmaCorp Rx Inc. Announces Management ChangesPharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m).Buy Or Sell Opportunity • Nov 21Now 24% overvaluedOver the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%.Recent Insider Transactions • Nov 16Executive Chairperson recently bought CA$1.0m worth of stockOn the 12th of November, Alan Simpson bought around 2m shares on-market at roughly CA$0.42 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.공고 • Nov 13PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million.PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 47,700,000 Price\Range: CAD 0.42 Discount Per Security: CAD 0.0252공고 • Aug 25PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025.Reported Earnings • Aug 18Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024)Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024).공고 • Aug 08PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc.PharmaCorp Rx Inc. (TSXV:PCRX) entered into share purchase agreement to acquire Pharmacy business from PharmaChoice Canada Inc. for CAD 2.4 million on June 24, 2025. The purchase price is subject to customary adjustments which will be paid using cash on hand. The Acquisition is expected to close on or about July 31, 2025, subject to satisfaction of customary closing conditions. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc on August 7, 2025.Buy Or Sell Opportunity • Jul 30Now 24% overvaluedOver the last 90 days, the stock has fallen 4.1% to CA$0.47. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.분석 기사 • Jul 28Calculating The Fair Value Of PharmaCorp Rx Inc. (CVE:PCRX)Key Insights PharmaCorp Rx's estimated fair value is CA$0.38 based on 2 Stage Free Cash Flow to Equity With CA$0.46...Buy Or Sell Opportunity • Jul 08Now 29% overvalued after recent price riseOver the last 90 days, the stock has risen 2.1% to CA$0.49. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Buy Or Sell Opportunity • Jun 04Now 24% overvaluedOver the last 90 days, the stock has fallen 9.8% to CA$0.46. The fair value is estimated to be CA$0.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only.New Risk • Feb 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (478% increase in shares outstanding). Revenue is less than US$1m (CA$1.4m revenue, or US$981k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$64.5m market cap, or US$45.3m).Board Change • Oct 04High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Ken Brownell was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공고 • Oct 03PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire Pharmacy business including land and buildings located in Atlanfic Canada for CAD 15.4 million on September 24, 2024. A cash consideration of CAD 15.18 million will be paid by PharmaCorp Rx Inc. The consideration consists of common equity of PharmaCorp Rx Inc. having a value of CAD 0.2 million to be issued for assets of Pharmacy business including land and buildings located in Atlanfic Canada. As part of consideration, CAD 15.38 million is paid towards assets of Pharmacy business including land and buildings located in Atlanfic Canada. For the period ending April 30, 2024, Pharmacy business including land and buildings located in Atlanfic Canada reported total revenue of CAD 10.36 million, net income of CAD 0.44 million, net assets of CAD 2.21 million and total debt of CAD 1.01 million. The transaction is subject to satisfaction of customary closing conditions, including the conditional acceptance of the TSX Venture Exchange. The expected completion of the transaction is October 1, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada on October 2, 2024.공고 • Sep 05PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transaction is that the Vendors will retain a 10% interest in the Acquired Pharmacy and have agreed to continue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada on September 3, 2024.공고 • Aug 23PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transacfion is that the Vendors will retain a 10% interest in the Acquired Pharmacy, and have agreed to confinue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024.공고 • Aug 22PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024.New Risk • Aug 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 366% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (366% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$43.8m market cap, or US$31.6m).Board Change • Jul 23High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Glenn Fradette is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공고 • Jun 08+ 1 more updateProton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million.Proton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 51,994,146 Price\Range: CAD 0.4공고 • May 29Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy.Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy on May 27, 2024.공고 • Nov 17Proton Capital Corp., Annual General Meeting, Jan 22, 2024Proton Capital Corp., Annual General Meeting, Jan 22, 2024.매출 및 비용 세부 내역PharmaCorp Rx가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSXV:PCRX 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2624-210031 Dec 2521-19030 Sep 251806030 Jun 251406031 Mar 2510-14031 Dec 246-13030 Sep 241-23030 Jun 240-11031 Mar 240-11031 Dec 23001030 Sep 23000030 Jun 23000031 Mar 230-11031 Dec 220-11030 Sep 220-110양질의 수익: PCRX 은(는) 현재 수익성이 없습니다.이익 마진 증가: PCRX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PCRX은 수익성이 없으며 지난 5년 동안 손실이 연평균 29.9% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PCRX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PCRX은 수익성이 없어 지난 해 수익 성장률을 Consumer Retailing 업계(15.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PCRX는 현재 수익성이 없으므로 자본 수익률이 음수(-2.93%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YConsumer-retailing 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/18 11:00종가2026/08/18 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PharmaCorp Rx Inc.는 3명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nick CorcoranAcumen Capital Finance Partners LimitedTania Armstrong-WhitworthCanaccord GenuityFred GataliRaymond James Ltd.
Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).
Reported Earnings • Aug 18Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024)Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024).
Recent Insider Transactions • Jul 17Executive Chairperson recently bought CA$88k worth of stockOn the 14th of July, Alan Simpson bought around 173k shares on-market at roughly CA$0.51 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Alan has been a buyer over the last 12 months, purchasing a net total of CA$1.1m worth in shares.
공고 • Jul 14PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 10.00008 million.PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 10.00008 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 19,608,000 Price\Range: CAD 0.51 Discount Per Security: CAD 0.0306
공고 • Jul 07PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) entered into definitive share purchase agreement to acquire Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on April 28, 2026. A cash consideration of CAD 24.2 million will be paid by PharmaCorp Rx Inc. subject to customary adjustments. As part of consideration, CAD 24.2 million is paid towards interests of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada. The consideration is expected to be funded using the Corporation’s existing cash resources. In addition, the Corporation has also entered into non-binding letters of intent (“LOIs”) in respect of four additional pharmacy acquisitions. All locations will continue to be operated by their existing managing pharmacists, ensuring continuity of care, preserving patient relationships, and supporting a seamless transition and integration into the PharmaCorp platform. The transaction is subject to customary closing conditions. The Transaction is expected to close within 60 days. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Eight PharmaChoice Canada bannered pharmacies in Eastern Canada from two unnamed vendor groups for approximately CAD 24.2 million on July 6, 2026.
Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).
공고 • Nov 29PharmaCorp Rx Inc. Announces Management ChangesPharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.
New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m).
Buy Or Sell Opportunity • Nov 21Now 24% overvaluedOver the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%.
Recent Insider Transactions • Nov 16Executive Chairperson recently bought CA$1.0m worth of stockOn the 12th of November, Alan Simpson bought around 2m shares on-market at roughly CA$0.42 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.
공고 • Nov 13PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million.PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 47,700,000 Price\Range: CAD 0.42 Discount Per Security: CAD 0.0252
공고 • Aug 25PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025.
Reported Earnings • Aug 18Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024)Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024).
공고 • Aug 08PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc.PharmaCorp Rx Inc. (TSXV:PCRX) entered into share purchase agreement to acquire Pharmacy business from PharmaChoice Canada Inc. for CAD 2.4 million on June 24, 2025. The purchase price is subject to customary adjustments which will be paid using cash on hand. The Acquisition is expected to close on or about July 31, 2025, subject to satisfaction of customary closing conditions. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc on August 7, 2025.
Buy Or Sell Opportunity • Jul 30Now 24% overvaluedOver the last 90 days, the stock has fallen 4.1% to CA$0.47. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
분석 기사 • Jul 28Calculating The Fair Value Of PharmaCorp Rx Inc. (CVE:PCRX)Key Insights PharmaCorp Rx's estimated fair value is CA$0.38 based on 2 Stage Free Cash Flow to Equity With CA$0.46...
Buy Or Sell Opportunity • Jul 08Now 29% overvalued after recent price riseOver the last 90 days, the stock has risen 2.1% to CA$0.49. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Buy Or Sell Opportunity • Jun 04Now 24% overvaluedOver the last 90 days, the stock has fallen 9.8% to CA$0.46. The fair value is estimated to be CA$0.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
New Risk • Feb 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (478% increase in shares outstanding). Revenue is less than US$1m (CA$1.4m revenue, or US$981k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$64.5m market cap, or US$45.3m).
Board Change • Oct 04High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Ken Brownell was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공고 • Oct 03PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire Pharmacy business including land and buildings located in Atlanfic Canada for CAD 15.4 million on September 24, 2024. A cash consideration of CAD 15.18 million will be paid by PharmaCorp Rx Inc. The consideration consists of common equity of PharmaCorp Rx Inc. having a value of CAD 0.2 million to be issued for assets of Pharmacy business including land and buildings located in Atlanfic Canada. As part of consideration, CAD 15.38 million is paid towards assets of Pharmacy business including land and buildings located in Atlanfic Canada. For the period ending April 30, 2024, Pharmacy business including land and buildings located in Atlanfic Canada reported total revenue of CAD 10.36 million, net income of CAD 0.44 million, net assets of CAD 2.21 million and total debt of CAD 1.01 million. The transaction is subject to satisfaction of customary closing conditions, including the conditional acceptance of the TSX Venture Exchange. The expected completion of the transaction is October 1, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada on October 2, 2024.
공고 • Sep 05PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transaction is that the Vendors will retain a 10% interest in the Acquired Pharmacy and have agreed to continue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada on September 3, 2024.
공고 • Aug 23PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transacfion is that the Vendors will retain a 10% interest in the Acquired Pharmacy, and have agreed to confinue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024.
공고 • Aug 22PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024.
New Risk • Aug 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 366% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (366% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$43.8m market cap, or US$31.6m).
Board Change • Jul 23High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Glenn Fradette is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공고 • Jun 08+ 1 more updateProton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million.Proton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 51,994,146 Price\Range: CAD 0.4
공고 • May 29Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy.Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy on May 27, 2024.
공고 • Nov 17Proton Capital Corp., Annual General Meeting, Jan 22, 2024Proton Capital Corp., Annual General Meeting, Jan 22, 2024.